Quick Takeaways
- T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G/A for KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI).
- Disclosed ownership: 14%.
- Date of event: 31 Oct 2025.
T. Rowe Price Investment Management, Inc. - 31 Oct 2025 SCHEDULE 13G/A Report for KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI)
- Filing Manager
- T. Rowe Price Investment Management, Inc.
- Reporting Manager
- T. Rowe Price Investment Management, Inc.
- Symbol
- KPTI
- Shares outstanding
- 16,697,406 shares
- Disclosed Ownership
- 2,304,242 shares
- Ownership
- 14%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 Nov 2025, 13:02:38 UTC
- Date of event
- 31 Oct 2025
- Previous filing
- 14 Aug 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"T. Rowe Price Investment Management, Inc. disclosed 14% ownership in KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI) on 31 Oct 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 07 Nov 2025, 13:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14% | 2,304,242 | 704,151 | 0 | Ellen York | Vice President |